USVI Response Measures

1. Prevent, delay, and mitigate transmission:
   Develop screening at ports of entry; provide best practices and guidance to organizations to reduce transmission; develop strategies for vulnerable populations.

2. Conduct surveillance:
   Inform the response based on epidemiologic data; liaise with healthcare sector to identify cases and define clinical and transmission characteristics; operate epi hotline; track persons under investigation; perform contact tracing of cases; conduct follow-up sampling of cases; coordinate with lab.

3. Provide public health & safety messaging:
   Develop communication strategy; build capacity with partners; provide daily report.

4. Provide medical guidance:
   Provide Infection Prevention and Control guidance related to healthcare personnel and health systems; provide guidance to clinicians on treatment and management of patients.

5. Conduct lab testing:
   Build laboratory testing capacity for VIDOH; explore external lab capacity; manage specimen collection and supplies.

6. Coordinate medical surge capacity:
   Assess resource needs and inventory resources (equipment, staff); develop a health and medical staffing strategy; prepare resource requests for material aid and staff (federal partner, EMAC, etc); develop resource management, utilization, and prioritization plan.

Testing Summary

<table>
<thead>
<tr>
<th></th>
<th>07-Jul</th>
<th>06-Jul</th>
<th>Change since 06-Jul</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total tested</td>
<td>3453</td>
<td>3354</td>
<td>▲ 99</td>
</tr>
<tr>
<td>Tested positive</td>
<td>122</td>
<td>116</td>
<td>▲ 6</td>
</tr>
<tr>
<td>Tested negative</td>
<td>3273</td>
<td>3183</td>
<td>▲ 90</td>
</tr>
<tr>
<td>Pending tests</td>
<td>58</td>
<td>55</td>
<td>▲ 3</td>
</tr>
</tbody>
</table>

Test result among males and females

- Males: n=64
- Females: n=1481
- Unknown: n=443

Test result by age group

- 0-17: n=58
- 18-49: n=64
- 50-64: n=1349
- 65+: n=58

Median age among cases = 46 years

Test positive

- 0-17: 3%
- 18-49: 4%
- 50-64: 4%
- 65+: 2%

Sample collection dates of persons under investigation for COVID-19 in the U.S. Virgin Islands

Illnesses that started during this time may not yet be reported.
**Confirmed COVID-19 cases in the U.S. Virgin Islands, N=122**

### Current status of cases
- **Active**: 36
- **Recovered**: 80
- **Fatality**: 6

### Risk factors for transmission
- **Community transmission**: 26
- **Close contact**: 51
- **Travel**: 37
- **Under investigation**: 8

### Clinical symptoms
<table>
<thead>
<tr>
<th>Symptom</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cough</td>
<td>66</td>
<td>54%</td>
</tr>
<tr>
<td>Fever*</td>
<td>64</td>
<td>52%</td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>31</td>
<td>25%</td>
</tr>
</tbody>
</table>

*Subjective fever or measured temp ≥100.4°F

### Change since 06-Jul

#### St. Croix
<table>
<thead>
<tr>
<th>Cases</th>
<th>07-Jul</th>
<th>06-Jul</th>
<th>Change since 06-Jul</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>71</td>
<td>65</td>
<td>▲ 6</td>
</tr>
<tr>
<td>Negative</td>
<td>1797</td>
<td>1756</td>
<td>▲ 41</td>
</tr>
<tr>
<td>Pending</td>
<td>43</td>
<td>46</td>
<td>▼ -3</td>
</tr>
</tbody>
</table>

#### Risk factors for transmission
- **Community transmission**: 8
- **Close contact**: 34
- **Travel**: 21
- **Under investigation**: 8

#### St. John
<table>
<thead>
<tr>
<th>Cases</th>
<th>07-Jul</th>
<th>06-Jul</th>
<th>Change since 06-Jul</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>4</td>
<td>4</td>
<td>▼ 0</td>
</tr>
<tr>
<td>Negative</td>
<td>139</td>
<td>138</td>
<td>▲ 1</td>
</tr>
<tr>
<td>Pending</td>
<td>1</td>
<td>1</td>
<td>▼ 0</td>
</tr>
</tbody>
</table>

#### Risk factors for transmission
- **Community transmission**: 1
- **Close contact**: 0
- **Travel**: 3
- **Under investigation**: 0

*ALL DATA ARE PROVISIONAL*